ProMIS Neurosciences (PMN) Retained Earnings (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Retained Earnings came in at -$371184.0 in Q1 2026, up 99.62% YoY from -$185944.1 in Q1 2025, and down 100.29% on a QoQ basis from $129.5 million in Q4 2025.
ProMIS Neurosciences (PMN) Retained Earnings (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Retained Earnings data on file, last reported at -$371184.0 in Q1 2026.
- Quarterly Retained Earnings rose 99.62% year-over-year to -$371184.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$371184.0 (up 99.62% YoY) and the FY2025 annual result came in at $129.5 million, up 34993.43% from the prior year.
- Retained Earnings fell to -$371184.0 in Q1 2026, from $129.5 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $129.5 million in Q4 2025 to a low of -$119.7 million in Q3 2025.
- A 5-year average of -$38.7 million and a median of -$36.7 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings plunged 63121.33% — and 2025, when it soared 34993.43%.
- Tracing PMN's Retained Earnings over 5 years: stood at -$195369.0 in 2022, then sank by 47740.72% to -$93.5 million in 2023, then surged by 99.6% to -$371184.0 in 2024, then soared by 34993.43% to $129.5 million in 2025, then slumped by 100.29% to -$371184.0 in 2026.
- The last three Retained Earnings figures came in at -$371184.0 (Q1 2026), $129.5 million (Q4 2025), and -$119.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 4.38 Bn |
| 10 | ProMIS Neurosciences | 135.44 Mn | 81.98 Mn | - | 200.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 200.15 Mn |
| Mar 31, 2026 | -371,184.00 |
| Dec 31, 2025 | 129.52 Mn |
| Sep 30, 2025 | -119.70 Mn |
| Jun 30, 2025 | -371,184.00 |
| Mar 31, 2025 | -98.00 Mn |
| Dec 31, 2024 | -371,184.00 |
| Sep 30, 2024 | -90.45 Mn |
| Jun 30, 2024 | -99.72 Mn |
| Mar 31, 2024 | -371,184.00 |
| Dec 31, 2023 | -93.47 Mn |
| Sep 30, 2023 | -371,184.00 |
| Jun 30, 2023 | -87.52 Mn |
| Mar 31, 2023 | -85.21 Mn |
| Dec 31, 2022 | -195,369.00 |
| Sep 30, 2022 | -73.00 Mn |
| Jun 30, 2022 | -138,442.00 |
| Dec 31, 2021 | -62.19 Mn |